Affordable Access

deepdyve-link
Publisher Website

The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma.

Authors
  • Bissler, John J1
  • Franz, David N2
  • Frost, Michael D3
  • Belousova, Elena4
  • Bebin, E Martina5
  • Sparagana, Steven6
  • Berkowitz, Noah7
  • Ridolfi, Antonia8
  • Kingswood, J Christopher9
  • 1 Division of Nephrology, St Jude Children's Research Hospital and Le Bonheur Children's Hospital, University of Tennessee Health Science Center, 49 North Dunlap Street, Memphis, TN, 38163, USA. [email protected]
  • 2 Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
  • 3 Minnesota Epilepsy Group, St Paul, MN, USA.
  • 4 Moscow Research Institute of Pediatrics and Pediatric Surgery, Moscow, Russia.
  • 5 University of Alabama School of Medicine, Birmingham, AL, USA.
  • 6 Texas Scottish Rite Hospital for Children, Dallas, TX, USA.
  • 7 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • 8 Novartis Pharmaceuticals S.A.S., Rueil-Malmaison, France. , (France)
  • 9 Royal Sussex County Hospital, Brighton, UK.
Type
Published Article
Journal
Pediatric Nephrology
Publisher
Springer-Verlag
Publication Date
Jan 01, 2018
Volume
33
Issue
1
Pages
101–109
Identifiers
DOI: 10.1007/s00467-017-3806-1
PMID: 28993887
Source
Medline
Keywords
License
Unknown

Abstract

Although everolimus is currently not indicated for this use, this analysis from EXIST-1 demonstrates its long-term efficacy and safety for the treatment of renal angiomyolipoma in pediatric patients undergoing treatment for TSC-associated SEGA.

Report this publication

Statistics

Seen <100 times